Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently approved treatment.


Clinical Trial Description

This was a Phase 3, multicenter, open-label, single-arm study of adalimumab in Japanese participants with generalized pustular psoriasis (GPP). The study included a 30-day screening period, a 52-week treatment period, and a 70-day follow-up period. The dose regimen of adalimumab used in this study was 80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02533375
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 3
Start date September 28, 2015
Completion date July 20, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04300686 - A Pilot Study in Severe Patients With Takayasu Arteritis. Phase 4
Recruiting NCT05590416 - A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
Completed NCT05909852 - A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants Phase 1
Recruiting NCT05155592 - Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients Phase 2
Recruiting NCT05015335 - The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage Phase 4